Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure
Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC
Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC